

## QUALIFIED FINANCIAL EXPERT • DEAL EXPERT • STRATEGIST



**SUSAN E. GRAF, RPh, MBA**  
908-672-8051 • [susanegraf@icloud.com](mailto:susanegraf@icloud.com)

**Board Chair & Audit Committee Chair, Finch Therapeutics Group, Inc.  
(NASDAQ: FNCH)**  
**Audit Committee Chair & Board Member, Kaleo Pharmaceuticals (private)**  
**Senior Advisor & Entrepreneur in Residence, Locust Walk**

### AREAS OF EXPERTISE

Susan is an accomplished biopharma executive with 25+ years of deep operating and global leadership experience across pre-clinical entrepreneurial start-ups, mid-cap public biotech and large pharma. She is uniquely familiar with the opportunities and challenges faced by growing companies progressing from pre-clinical to clinical and onto commercial stage. Susan is well versed in public company governance, stemming from her time as a corporate officer, board member and board chair. Her companies have benefitted from her track record of value creating deals, strong industry connections, capital markets experience and strategic acumen.

Susan currently chairs both the board the audit committee at Finch, a clinical stage microbiome company (Mar 2021 NASDAQ IPO). In her time at Finch, she ensured a smooth transition as a public company, oversaw a major strategic pivot and continues to serve as a thought partner to the CEO. For Kaleo Pharmaceuticals, Susan chairs the audit committee and serves on the compensation committee. Kaleo is a commercial stage company dedicated to building innovative solutions for serious and life-threatening medical conditions.

---

Across her executive leadership roles, Susan has led and concluded impactful acquisitions, product collaborations and discovery deals, both on the buy-side and sell-side. Susan is currently a Senior Advisor and Entrepreneur in Residence at Locust Walk, where she advises on strategic transactions, equity financings and builds the NewCo formation practice. For resulting NewCos, Susan often serves as the company's first executive. In her prior CEO experience, at Akamara Therapeutics, she was instrumental in setting the vision and mission, shaping the leadership, progressing the scientific understanding of a novel cancer immunotherapy target and advancing its' Investigational New Drug (IND) application, all during the COVID-19 pandemic.

Previously, Susan served as an officer at NPS Pharma and Epizyme, both NASDAQ listed public companies. As Epizyme's Principal Financial Officer and Chief Business Officer, Susan raised \$160 million in public capital, oversaw the preparation of the company's financial statements and SEC filings and worked closely with the audit committee on financial planning and capital allocation to create value.

As NPS Pharma's Vice President of Corporate Development and Strategy, Susan was intimately involved in the company's \$5.2B sale to Shire in 2015. For two years leading up to the company sale, Susan shaped NPS' strategy and served on the executive team that transformed NPS into a global, commercial-stage, rare-disease company. Prior to NPS Pharma, Susan spent nearly 18 years at Roche in a number of leadership and executive positions in business development, mergers & acquisitions, marketing, market research, sales and manufacturing.

Past board roles include: Akamara Therapeutics (oncology, private) and Vitrisa Therapeutics (ophthalmology, private).

Susan was recognized as a Healthcare Businesswomen's Association Rising Star in 2011 and named to Purdue University's '40 Under 40' list. Susan earned an M.B.A. (Finance and Marketing focus) from the Stern School of Business at New York University, and a Bachelor of Pharmacy degree from Purdue University. She currently resides in Newton, Massachusetts.